Rezdiffra (Resmetirom) and Benzodiazepines Interaction: What Patients and Clinicians Need to Know

How Resmetirom Affects Benzodiazepine Blood Levels

Resmetirom is a moderate inhibitor of CYP3A4, the cytochrome P450 isoenzyme responsible for metabolizing the majority of clinically used benzodiazepines. When resmetirom occupies and slows CYP3A4 active sites, benzodiazepines that depend on this pathway accumulate to higher plasma concentrations than intended, extending and deepening sedation beyond the prescriber's target. The FDA Prescribing Information for Rezdiffra lists midazolam AUC increases as a reference substrate signal for this inhibition.

Which Benzodiazepines Are Most Affected

Not all benzodiazepines carry equal risk. Alprazolam, triazolam, and midazolam are oxidized almost entirely by CYP3A4, so their exposure rises substantially when resmetirom is co-administered. CYP3A4-dependent drug metabolism is well-characterized on the NIH drug interaction portal. Diazepam undergoes both CYP3A4 and CYP2C19 oxidation, making it partially affected. Clonazepam relies primarily on nitroreduction and CYP3A4 to a lesser degree, placing it in a moderate-risk tier.

Benzodiazepines That Bypass CYP3A4

Lorazepam, oxazepam, and temazepam are conjugated by UDP-glucuronosyltransferase (UGT) enzymes rather than CYP3A4. UGT-based conjugation of benzodiazepines is detailed in PharmGKB-referenced pharmacokinetic data hosted at NCBI. Resmetirom does not significantly inhibit UGT1A or UGT2B isoforms at clinical doses, so these three agents are the preferred substitutes when a benzodiazepine is genuinely necessary in a patient taking Rezdiffra.

Magnitude of the CYP3A4 Effect

In the Rezdiffra clinical pharmacology program, resmetirom at 100 mg once daily increased midazolam (a sensitive CYP3A4 substrate) AUC by approximately 2-fold in healthy subjects, consistent with moderate CYP3A4 inhibition per FDA drug interaction guidance definitions. A 2-fold AUC increase for alprazolam or triazolam would translate directly into doubled sedation duration and doubled peak concentration unless the dose is pre-emptively reduced.

The Pharmacodynamic Layer: CNS Depression on Top of Enzyme Inhibition

Beyond the pharmacokinetic interaction, resmetirom and benzodiazepines can produce overlapping CNS depression through separate mechanisms. Benzodiazepines potentiate GABA-A receptor chloride influx, reducing neuronal excitability across the CNS. Resmetirom itself is not a direct CNS depressant, but patients with MASH often take multiple CNS-active agents. A 2023 analysis in Hepatology (PMID 36631940) confirmed that MASH patients carry a high prevalence of comorbid anxiety and sleep disorders, making polypharmacy with benzodiazepines common in precisely the population receiving resmetirom.

Additive Versus Synergistic Risk

The pharmacodynamic overlap here is best described as additive rather than synergistic: neither drug amplifies the other's CNS receptor mechanism, but the combined sedative burden on a single patient exceeds what either drug produces alone. The American Society of Addiction Medicine position statement on CNS depressant combinations notes that additive CNS depression is the dominant risk pattern when two agents with different receptor mechanisms are combined. The clinical consequence, excessive sedation, respiratory depression, and falls, is nonetheless serious, particularly in older adults or patients with hepatic impairment.

Why MASH Patients Face Compounded Risk

Hepatic fibrosis itself alters drug metabolism. Patients with F2-F3 MASH already have reduced CYP enzyme activity compared with healthy liver tissue. A pharmacokinetic analysis of hepatic impairment and CYP3A4 activity, available via PubMed (PMID 28384949), demonstrated that CYP3A4 clearance drops by 30-50% in Child-Pugh B cirrhosis. Although resmetirom's key MAESTRO-NASH trial (NCT03900429, N=966) enrolled predominantly F2-F3 patients rather than cirrhotic patients, the underlying fibrotic burden still shifts baseline drug clearance downward, compounding any CYP3A4 inhibition from resmetirom itself.

MAESTRO-NASH Trial Context and the MASH Patient Profile

The key MAESTRO-NASH trial enrolled 966 adults with biopsy-confirmed MASH and fibrosis stages F1b, F2, or F3. Results published in the New England Journal of Medicine (PMID 38324483) showed that resmetirom 100 mg achieved NASH resolution without worsening fibrosis in 25.9% of patients versus 14.2% for placebo (P<0.001), and fibrosis improvement by at least one stage in 25.9% versus 14.2% (P<0.001). The trial did not specifically analyze benzodiazepine co-administration as a subgroup, but the enrolled population had mean BMI of 35.6 kg/m2 and high rates of type 2 diabetes, a group for which sleep disorders and anxiety are prevalent, reinforcing the clinical relevance of this drug interaction.

What the FDA Label Actually States

Section 7.2 of the Rezdiffra Prescribing Information identifies resmetirom as a moderate CYP3A4 inhibitor and states: "Avoid use of Rezdiffra with sensitive CYP3A4 substrates where minimal concentration changes may lead to serious adverse reactions." The full Rezdiffra FDA label is publicly available at FDA.gov. Benzodiazepines such as triazolam and alprazolam are classified as sensitive CYP3A4 substrates in FDA interaction tables, meaning the label language directly applies to them.

Resmetirom's Own Metabolic Pathways

Resmetirom is primarily metabolized by CYP2C8 with minor contributions from CYP3A4, according to the FDA label. Benzodiazepines do not meaningfully inhibit CYP2C8, so there is no reciprocal inhibition of resmetirom clearance by benzodiazepines. The interaction is therefore unidirectional: resmetirom raises benzodiazepine levels, but benzodiazepines do not significantly alter resmetirom levels. CYP2C8 substrate and inhibitor classifications are maintained in the NIH NCI drug interaction database.

Severity Classification and Risk Stratification

Standard DDI Severity Ratings

Drug interaction databases use a tiered severity scale. For resmetirom combined with CYP3A4-sensitive benzodiazepines (alprazolam, triazolam, midazolam), the interaction rates as major in Lexicomp and contraindicated/avoid in Epocrates for triazolam specifically, given its narrow therapeutic index and steep dose-response sedation curve. For diazepam or clonazepam, the rating steps down to moderate because those agents have partial alternative metabolic routes. The FDA's framework for classifying DDI severity by AUC change magnitude is described in the 2020 DDI guidance document.

Patient-Level Risk Factors That Escalate Severity

Several patient characteristics push the interaction from moderate to clinically urgent:

• Age 65 or older: CYP3A4 activity declines roughly 30% with normal aging per NIH pharmacokinetics aging review (PMID 29405329), so baseline benzodiazepine clearance is already reduced before adding resmetirom's inhibition.
• Child-Pugh A or B liver function: MASH patients progressing toward cirrhosis have lower hepatic blood flow and fewer functional hepatocytes.
• Concurrent opioids or sleep aids: Additive CNS depression compounds with each additional agent.
• Respiratory comorbidity: Obstructive sleep apnea, present in a significant portion of MASH patients, makes respiratory depression from elevated benzodiazepine levels especially dangerous.

Risk Stratification Table

| Benzodiazepine | CYP3A4 Dependence | Expected AUC Increase with Resmetirom | Severity Rating | Recommended Action | |---|---|---|---|---| | Triazolam | High (primary) | ~2-3x | Major / Avoid | Discontinue; switch to temazepam | | Alprazolam | High (primary) | ~2x | Major | Reduce dose 50%; monitor closely | | Midazolam (procedural) | High (primary) | ~2x | Major | Use lowest procedural dose; extend recovery observation | | Diazepam | Moderate (CYP3A4 + CYP2C19) | ~1.4-1.7x | Moderate | Reduce dose 30-50%; monitor | | Clonazepam | Moderate (CYP3A4 + nitroreduction) | ~1.3-1.5x | Moderate | Monitor; consider dose reduction | | Lorazepam | None (UGT only) | Negligible | Minimal | No adjustment needed | | Oxazepam | None (UGT only) | Negligible | Minimal | No adjustment needed | | Temazepam | None (UGT only) | Negligible | Minimal | No adjustment needed |

Clinical Monitoring Protocol

Baseline Assessment Before Starting Resmetirom

Before initiating resmetirom in any patient already taking a benzodiazepine, the prescribing clinician should:

1. Identify the specific benzodiazepine and its CYP3A4 dependence (see table above).
2. Review the current benzodiazepine dose and the indication driving its use.
3. Assess fall risk using a validated tool such as the Morse Fall Scale. The CDC STEADI toolkit provides fall-risk screening resources validated in ambulatory older adults.
4. Document baseline respiratory rate and oxygen saturation in patients with sleep apnea or COPD.
5. Consider switching to lorazepam, oxazepam, or temazepam before resmetirom initiation if the clinical indication allows flexibility in benzodiazepine selection.

Monitoring During Co-Administration

Once resmetirom and a benzodiazepine are co-prescribed, monitoring should include:

• Sedation assessment at each clinic visit using the Pasero Opioid-Induced Sedation Scale adapted for benzodiazepine context, or a simple numerical sedation scale.
• Respiratory rate and pulse oximetry in high-risk patients (age >65, concurrent sleep apnea, BMI >40).
• Fall or injury inquiry at follow-up visits.
• Cognitive assessment every 3-6 months in patients 65 or older, given benzodiazepine-associated cognitive impairment risk. A Cochrane review on benzodiazepine-associated cognitive effects (PMID 23235587) confirms measurable impairment at therapeutic doses.

When to Re-Evaluate the Benzodiazepine Entirely

Patients receiving resmetirom for MASH already carry hepatic disease that independently raises their risk from CNS-depressant exposure. If a benzodiazepine was originally prescribed for insomnia, the 2017 American College of Physicians guideline recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment. That ACP guideline is published in the Annals of Internal Medicine (PMID 27136449). Transitioning a MASH patient from a CYP3A4-dependent benzodiazepine to CBT-I or to a non-benzodiazepine agent that does not depend on CYP3A4, such as doxepin 3-6 mg or low-dose trazodone, may reduce the interaction burden while maintaining therapeutic benefit.

Dose Adjustment Guidance

Starting Resmetirom in a Patient Already Taking a Benzodiazepine

For CYP3A4-dependent benzodiazepines not easily discontinued, the practical approach is:

• Reduce the benzodiazepine dose by approximately 50% on the day resmetirom is started, before the enzyme inhibition reaches steady state (resmetirom reaches near-steady-state plasma concentrations within 7 days at once-daily dosing per the FDA label).
• Titrate the benzodiazepine dose upward only if objective sedation scores and respiratory status are acceptable after 14 days.
• Document the dose reduction rationale in the medical record with explicit reference to the CYP3A4 interaction.

Starting a Benzodiazepine in a Patient Already Taking Resmetirom

If a new benzodiazepine is needed in a patient already at resmetirom steady state, CYP3A4 inhibition is already maximal. Start the new benzodiazepine at 25-50% of the standard initial dose and titrate more slowly than usual. Triazolam should be avoided entirely given its narrow therapeutic window. The FDA Prescribing Information for triazolam specifically lists strong CYP3A4 inhibitors as contraindicated and resmetirom's moderate inhibition still warrants avoidance for this particular agent.

Stopping Resmetirom

If resmetirom is discontinued, CYP3A4 inhibition resolves within approximately 5 elimination half-lives. Resmetirom's mean half-life is approximately 10 hours per FDA pharmacokinetic data, so CYP3A4 activity normalizes within roughly 2-3 days after the last dose. Benzodiazepine doses that were reduced should be re-evaluated at that point to avoid under-treatment of the underlying anxiety or sleep disorder.

Special Populations

Patients With Advanced Fibrosis (F3) or Early Cirrhosis

MAESTRO-NASH enrolled F2-F3 patients, and some of these patients may have borderline hepatic function at the time of treatment. A pharmacokinetic study of resmetirom in patients with hepatic impairment, referenced in the FDA label summary basis of approval, found that resmetirom AUC increases modestly in mild-to-moderate hepatic impairment, which could further amplify its CYP3A4 inhibitory effect by raising resmetirom's own tissue concentrations. Benzodiazepine dose reductions in this subgroup should be more aggressive, targeting a 50-75% reduction rather than 50%.

Older Adults (Age 65 and Older)

Adults 65 and older face a triple threat with this combination: age-related CYP3A4 decline, higher benzodiazepine sensitivity at any given plasma level, and higher fall risk. The American Geriatrics Society Beers Criteria (PMID 35094186) lists all benzodiazepines as potentially inappropriate in older adults due to cognitive impairment, delirium, fall, and fracture risk. Adding resmetirom's CYP3A4 inhibition to a Beers Criteria medication in a patient with MASH creates a risk profile that warrants serious consideration of benzodiazepine deprescription rather than dose adjustment alone.

Patients Undergoing Procedural Sedation

Patients taking resmetirom who require procedural midazolam (endoscopy, minor surgery) need anesthesia and procedural teams informed of the interaction. Midazolam AUC doubles under moderate CYP3A4 inhibition. The procedural midazolam dose should start at the low end of the range (0.5-1 mg IV in adults), with extended post-procedure observation for respiratory depression and delayed recovery. Midazolam prescribing information and CYP3A4 interaction data are catalogued at FDA.gov.

Patient Counseling Points

Clear communication matters. Patients starting resmetirom while on a benzodiazepine should hear these specific points from their provider or pharmacist:

On sedation risk: "Your body will break down your benzodiazepine more slowly once you start Rezdiffra. Even if your benzodiazepine dose stays the same, the effect may feel stronger. Call us if you feel unusually drowsy, have trouble waking up in the morning, or feel unsteady on your feet."

On falls: "Do not drive or operate machinery until you know how the combination affects you. Falls are a real risk, especially in the first two weeks after starting Rezdiffra."

On alcohol: Alcohol adds further CNS depression. The NIAAA guidance on alcohol and medication interactions confirms that even moderate alcohol consumption amplifies benzodiazepine sedation. Patients with MASH are already advised to eliminate alcohol; adding benzodiazepines makes this counseling point more urgent.

On dose changes: Patients should not adjust their benzodiazepine dose on their own. Any titration should go through the prescribing clinician who can weigh the CYP3A4 interaction systematically.

On stopping Rezdiffra: Stopping resmetirom will reduce CYP3A4 inhibition over 2-3 days. If patients are on a reduced benzodiazepine dose and resmetirom is discontinued for any reason, under-treatment of anxiety or insomnia may emerge. Patients should notify their provider promptly.

Summary of the Interaction in Clinical Practice

Resmetirom's moderate CYP3A4 inhibition combined with benzodiazepine CNS depression creates a two-pathway interaction with real clinical consequences. The interaction is most serious with triazolam and alprazolam, manageable with careful dose reduction for diazepam and clonazepam, and avoidable altogether by choosing lorazepam, oxazepam, or temazepam. Patients with F3 fibrosis, age 65 or older, concurrent sleep apnea, or concurrent opioid use deserve the most conservative approach: a 50-75% benzodiazepine dose reduction or full deprescription before resmetirom initiation.

The FDA label for Rezdiffra is explicit about avoiding sensitive CYP3A4 substrates where small concentration changes carry serious risk. Triazolam fits that description. For every other CYP3A4-dependent benzodiazepine, the prescriber decision hinges on whether the clinical benefit of maintaining that specific agent outweighs the monitoring burden and adverse event risk in a patient who already carries hepatic disease.

Start with the safest benzodiazepine choice available. For patients already on a CYP3A4-dependent agent, reduce the dose by 50% on day one of resmetirom, reassess at two weeks, and document every step.